Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (2015-2025)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's disease
Tập 4 Số 1 - Trang 575-590 - 2018
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro...
Alzheimer's disease drug development pipeline: 2018
Tập 4 Số 1 - Trang 195-214 - 2018
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in...
Alzheimer's disease drug development pipeline: 2017
Tập 3 Số 3 - Trang 367-384 - 2017
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are...
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
Tập 3 Số 3 - Trang 291-300 - 2017
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and...
Accelerating drug development for Alzheimer's disease through the use of data standards
Tập 3 - Trang 273-283 - 2017
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for...
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Tập 4 - Trang 444-449 - 2018
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe...
A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
Tập 5 - Trang 20-26 - 2019
AbstractBackgroundElayta (CT1812) is a novel allosteric antagonist of the
sigma‐2 receptor complex that prevents and displaces binding of Aβ oligomers to
neurons. By stopping a key initiating event in Alzheimer's disease, this
first‐in–class drug candidate mitigates downstream synaptotoxicity and restores
cognitive function in aged transgenic mouse models of Alzheimer's
disease.MethodsA phase 1, t...
An 8‐week, open‐label, dose‐finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations
Tập 3 - Trang 507-512 - 2017
AbstractIntroductionFrontotemporal lobar degeneration–causing mutations in the
progranulin (GRN) gene reduce progranulin protein (PGRN) levels, suggesting that
restoring PGRN in mutation carriers may be therapeutic. Nimodipine, a Food and
Drug Administration–approved blood‐brain barrier‐penetrant calcium channel
blocker, increased PGRN levels in PGRN‐deficient murine models. We sought to
assess sa...
Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets
Tập 5 - Trang 515-523 - 2019
AbstractThere exist a large number of cohort studies that have been used to
identify genetic and biological risk factors for developing Alzheimer's disease
(AD). However, there is a disagreement between studies as to how strongly these
risk factors affect the rate of progression through diagnostic groups toward AD.
We have calculated the probability of transitioning through diagnostic groups in
si...
A systematic review of the use of virtual reality and its effects on cognition in individuals with neurocognitive disorders
Tập 5 - Trang 834-850 - 2019
AbstractIntroductionVirtual reality (VR) interventions are increasingly used in
individuals with brain injuries. The objective of this study was to determine
the effects of VR on overall cognitive functioning in individuals with
neurocognitive disorders (NCDs).MethodsUsing Preferred Reporting Items for
Systematic Reviews and Meta‐Analyses guidelines, a systematic review of the
published literature...